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SUMMARY
Objective: To compare the rates of overall survival (OS), disease-free survival (DFS) and tox-
icity in different techniques of postoperative radiotherapy for stage IA endometrioid adeno-
carcionoma of endometrium, histological grades 1and 2. Methods: A historical comparison 
between treatment regimens was performed, and 133 women with a minimum follow-up 
of 5 years were included. Teletherapy (TELE group), with 22 patients treated from 1988 to 
1996, with a 10 MV linear accelerator, average dose 46.2 Gy. Low dose rate brachytherapy 
(LDRB group) was performed between 1992 and 1995, in 19 women, with an insertion of 
Cesium 137, at a 60  Gy dose. Fourteen women operated between 1990 and 1996 did not 
receive radiotherapy (NO RT group). High dose rate brachytherapy was performed in 78 pa-
tients (HDRB group), from 1996 to 2004, in five weekly 7 Gy insertions, prescribed at 0.5 cm 
from the vaginal cylinder. Results: The 5-year disease-free survival was 94.6% for the HDRB 
group, 94.1% for the LDRB group, 100% for the TELE group and NO RT groups (p = 0.681). 
The 5-year overall survival was 86.6% for the HDRB group, 89.5% for the LDRB group and 
90% for the TELE group and NO RT groups (p = 0.962). Grades 3-5 late toxicity was 5.3% 
in LDRB group and 27.3% for the TELE group (p < 0.001).  Conclusion: Patients submitted 
to adjuvant teletherapy showed very high toxicity, which contraindicates that treatment for 
those patients. There may be a role for adjuvant HDRB, but randomized controlled trials are 
still needed to evaluate its benefit.
Keywords: Genital neoplasms, female; radiotherapy, adjuvant; brachytherapy; endometrial 
neoplasms.
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INTRODUCTION
Surgery is the primary treatment for stage 1 endometrial 
cancer, and radiotherapy can be used as adjuvant treat-
ment. Medical literature has not defined the best adjuvant 
treatment for stage 1A endometrial cancer, histological 
grades 1 and 21. Teletherapy is advocated by some authors, 
high dose rate brachytherapy (HDRB) by others, and also 
low dose rate brachytherapy (LDRB) has been described2-7. 
There are also authors who question the use of any adju-
vant radiotherapy8,9.
A meta-analysis evaluated the benefit of adjuvant tele-
therapy in cancer of endometrium stage I. With four ran-
domized controlled trials included, 1,770 patients were 
analyzed, with 870 in the treatment group and 900 in the 
control group. There was a reduction of 72% in the risk of 
loco-regional recurrence, p < 0.00001, with NNT (number 
needed to treat) of 16.7 to prevent a recurrence. There was 
no difference between the rates of distant recurrence, over-
all survival, and deaths, but higher toxicity10.
There are no randomized controlled trials comparing 
adjuvant brachytherapy and teletherapy for endometrial 
carcinoma, stage IA, histological grades 1 and 2 carriers. 
The question remains, whether vaginal brachytherapy can 
bring local control benefit comparable to teletherapy. We 
can not say if the toxicity for these treatments is similar, 
just for lack of such clinical trials. Given these consider-
ations, this study was conducted, as a retrospective analy-
sis of sequential series. It reports comparative results of en-
dometrial cancer patients, stage IA, grades 1 and 2, treated 
with LDRB, HDRB and teletherapy.
METHODS
PATIENTS
This is a historical comparison between treatment regi-
mens. Between 1988 and 2004, 133 women with uterine 
endometrioid adenocarcinoma, FIGO stage IA (less than 
half myometrial invasion), histological grades 1 and 2, 
underwent surgery at the department of Gynecology 
and Obstetrics, Medical School, Universidade Estadual 
de Campinas, Campinas, Brazil. Before 1996, some of 
them received no adjuvant treatment, and others were 
submitted to teletherapy or LDRB. In 1996, with the 
introduction of HDRB, all patients received adjuvant 
HDRB. These patients had a minimum follow-up of 5 
years, and their treatment results were retrospectively 
evaluated, with progression-free survival, overall surviv-
al and toxicity as endpoints. Table 1 summarizes patient 
characteristics.
The HDRB group with 78 patients and mean age 62.9 
years was treated between 1996 and 2004 with Nucletron 
micro-Selectron HDRB with the largest vaginal cylinder 
possible. They received five weekly 7  Gy fractions, pre-
scribed to 0.5 cm of the applicators, 4 cm length, total dose 
of 35  Gy. This fractioning regimen was calculated based 
on Dale radiobiological equations11. Bladder and rectum 
doses were not calculated. 
The LDRB group, with 19 patients and a mean age 64.9 
years was treated between 1992 and 1995, received one in-
sertion of LDRB, with Cesium 137, in vaginal vault, receiv-
ing a dose of 60 Gy at the cilinder, in the upper two thirds 
of vaginal cuff length.
Table 1 – Patient characteristics according to treatment group
Characteristic HDRB LDRB TELE NO RT# p value
Patient number 78 19 22 14 –
Age – mean 62.9 64.9 62.4 63.1
(standard deviation) (8.4) (7.1) (9.5) (8.8) 0.783*
Follow-up in months-mean 88.9 118.1 99.0 102.6
(standard deviation) (35.3) (49.9) (48.7) (58.1) 0.057*
Lost to follow-up 4 0 3 2
(%) (6.3) (0.0) (13.6) (9.1) 0.1 54+
Surgery (%)
Hysterectomy + lymphadenectomy 50 (64.1) 18 (94.7) 15 (68.2) 8 (66.7)
Hysterectomy 28 (35.9) 1 ( 5.3) 7 (31.8) 4 (33.3) 0.0 77+
Histological grade (%)
I 48 (61.5) 9 (47.4) 6 (27.3) 5 (45.5)
II 30 (38.5) 10 (52.6) 16 (72.7) 6 (54.6) 0.0 35+
Linfovascularinvasion (%)
Positive 1 (1.3) 0 (0.0) 3 (13.6) 0 (0.0)
Negative 77 (98.7) 19 (100.0) 19 (86.4) 12 (100.0) 0.018+
*ANOVA test; + chi-square test; # two patients died from surgery complications and were excluded from analysis.
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Teletherapy group, 22 patients with a mean age 
62.4 years, was treated between 1988 and 1996, with pho-
ton beam energy in a 10 MV megavoltage linear accelera-
tor, using the four-field technique. Anteroposterior superi-
or borders fields were between L4 and L5, inferior borders 
at the obturator foramen and lateral limits were 1.5  cm 
lateral to pelvic brim. Lateral fields had anterior borders 
at the pubic symphysis, and posterior borders between S2 
and S3. Doses ranged from 45 to 52.2 Gy (mean: 46.2 Gy), 
in daily 1.8-2 Gy, fractions 5 times a week.
NO RT group, with 14 patients, mean age 63.1 years, 
operated between 1990 and 1996, had no adjuvant radio-
therapy.
FOLLOW-UP AND STATISTICAL ANALYSIS
After treatment, patients were reassessed every four 
months during the first two years, every six months un-
til the fifth year, and annually thereafter, on the basis of 
clinical examination, oncotic colpocytology, pelvic ultra-
sound and laboratory tests. They were followed up for at 
least five years. Overall survival (OS) time was measured 
from the date of surgery to the date of death or the most 
recent follow-up, progression free survival (PFS) as period 
from time of surgery to date of first documented evidence 
of progressive disease. Treatment toxicity was graded ac-
cording to toxicity criteria of the radiation therapy oncol-
ogy group (RTOG)12.
The Kaplan-Meier method was used to generate sur-
vival curves to compare treatment results. A Log-Rank test 
was used to analyze the results. Patients without recurrent 
disease were censored at their last follow-up visit or death. 
For all statistical tests, p < 0.05 was considered significant. 
All statistical analyses were performed using SPSS soft-
ware (version 11.01. for windows) Leadtoolsq 1991-2000 
LEAD Technologies Inc.
This study was reviewed and approved by the research 
ethics committee of the institution.
RESULTS
Table  2 shows the patients status by treatment group, at 
the end of follow-up. The 5-year disease-free survival was 
94.6% for HDRB group, 94.1% for LDRB group, 100% for 
TELE group and 100% for the NO RT group (p = 0.681). 
The 5-year overall survival was 86.7% for the HDRB 
group, 89.5% for the LDRB group, 89.9% for the TELE 
group and 90.1% for the NO RT group.
Toxicity was described using the criteria of the Radia-
tion therapy oncology group (RTOG)12. Grades 1 and 2 
radiotherapy-related late toxicity was 18% for HDRB 
group, 10.5% for the LDRB group, and 1% for the 
TELE group. Grades 3-5 late toxicity did not occur in 
HDRB group, but was 5.3% in LDRB group and 27.3% 
for the TELE group (p < 0.001). There was no significant 
statistical relation between lymphadenectomy and higher 
toxicity, and the worsening of severe toxicity was related to 
radiation dose above 45  Gy (p  < 0.001). Table  3 reports 
toxicity details.
According to Cox, acute lower G.I. toxicity, includ-
ing pelvis is graded as 0 when there is no change. Grade 
1 with increased frequency or change in quality of bowel 
habits, not requiring medication, rectal discomfort not 
requiring analgesics. Grade 2, includes diarrhea requiring 
parasympatholytic drugs, mucous discharge not necessi-
tating sanitary pads, rectal or abdominal pain requiring 
analgesics. Grade 3 diarrhea requiring parenteral support, 
severe mucous or blood discharge necessitating sanitary 
pads, abdominal distention. Grade 4, acute or subacute 
obstruction, fistula or perforation, GI bleeding requiring 
transfusion, abdominal pain or tenesmus requiring tube 
decompression or bowel diversion. Grade 5, death related 
to radiation effects.
The acute genitourinary toxicity is graded as 0, when 
there is no change. Grade 1, frequency of urination or noc-
turia, twice pretreatment habit, dysuria, urgency not requir-
ing medication. Grade 2, frequency of urination or noctu-
ria, that is less frequent than every hour. Dysuria, urgency, 
bladder spasm requiring local anesthetic. Grade 3, frequen-
cy with urgency and nocturia hourly or more frequently, 
dysuria, pelvis pain or bladder spasm requiring regular, 
frequent narcotic/gross hematuria with or without clot pas-
sage. Grade 4, hematuria requiring transfusion, acute blad-
der obstruction not secondary to clot passage, ulceration, 
or necrosis. Grade  5, death related to radiation effects.
Cronic GI toxicity, grade 0 no change. Grade 1 mild 
diarrhea; mild cramping; bowel movement 5 times dai-
ly; slight rectal discharge or bleeding. Grade 2, moder-
ate diarrhea and colic; bowel movement > 5  times daily; 
Table 2 – Survival and estimated relative risks by treatment group
Treatment
Patients
(n)
OS+ (%)
at 5 years
Hazards ratio*
(95% Cl)
DFS# (%)
at 5 years
Hazards ratio*
(95% Cl)
HDRB 78 86.7 1.0 94.6 1.0
LDRB 19 89.5 0.8 (0.2-3.8) 94.1 0.5 (0.6-4.3)
TELE 22 89.9 0.8 (0.2-3.6) 100.0 0.5 (0.7-3.7)
NO RT 12 90.1 0.7 (0.9-6.2) 100.0 0.9 (0.1-6.5)
* Hazards ratio and 95% confidence intervals obtained from a Cox model; + overall survival; # disease-free survival.
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excessive rectal mucus or intermittent bleeding. Grade 3, 
obstruction or bleeding, requiring surgery. Grade 4 ne-
crosis, perforation and fistula. Grade 5, death related to 
radiation effects.
Cronic genitourinary toxicity is grade 0 when there is 
no change. Grade 1 slight epithelial atrophy; minor tel-
angiectasia (microscopic hematuria). Grade 2 moderate 
frequency; generalized telangiectasia; intermittent mac-
roscopic hematuria. Grade 3 severe frequency and dys-
uria, frequent hematuria; reduction in bladder capacity 
(< 150 cc). Grade 4, necrosis, contracted bladder (capac-
ity < 100 cc), severe hemorrhagic cystitis. Grade 5, death 
related to radiation effects12.
DISCUSSION
The current study used a time-series design to evaluate 
outcomes and toxicity in adjuvant treatment for FIGO 
stage IA endometrial adenocarcinoma, histological grades 
1 and 2. There was no difference in DFS and OS for the 
different radiotherapy regimens, even when compared to 
no radiotherapy at all. 
Aalders et al.13 published a randomized study with 
540 patients, FIGO old stages IB and IC, including IB, 
histological grade 114. The patients were operated without 
lymphadenectomy and received low dose rate brachy-
therapy in vaginal vault, dose of 6,000 cGy, then random-
ized into two groups: observation and pelvic teletherapy, 
dose of 4,000 cGy. In a 3 to 10 years follow-up, the group 
that received teletherapy showed lower pelvic and vaginal 
recurrence (1.9 x 6.9%, p < 0.01) but no improvement in 
overall survival.
The PORTEC study15 included 715 patients with stage I, 
from 19 radiotherapy centers. They were submitted to sur-
gery, without lymphadenectomy, but with palpation and 
biopsy of suspicious nodes. After the surgery, they were 
randomized between adjuvant teletherapy with 4,600 cGy 
or no other treatment. In a median follow-up of 52 
months, there was a significant reduction of local recur-
rence in five years (4% x 14%, p < 0.001), but worsening 
toxicity. There was no significant difference in survival at 
five years (81% x 85%, p = 0.31)16. Data of this study was 
updated to a mean 94 months follow-up, with local recur-
rence at 10 years of 5% in the group with radiotherapy and 
14% in the group without radiotherapy (p < 0.0001) and 
overall survival at 10 years of 66% for radiotherapy group 
and 73% for the group without radiotherapy (p  =  0.09), 
showing again the radiation influence on local control, but 
without impact on overall survival, even excluding the pa-
tients stage IA grade 1 after pathological review.
The GOG 9917 study included 448 women with old 
FIGO stages IB, IC and II (occult disease), and 392 (88%) 
were considered eligible. The surgery included pelvic 
and para-aortic lymphadenectomy, and subsequent ran-
domization to teletherapy with 5,040 cGy to pelvis or no 
other additional treatment. With a mean follow-up of 68 
months, the group submitted to external radiotherapy 
had a reduction in recurrence risk by 58% (p = 0.007). 
The estimated survival at four years for the control group 
was 86% and 92% for the group that received radiother-
apy. This improvement in survival did not reach statisti-
cal significance (p = 0.557). The authors concluded that 
radiotherapy reduces the risk of recurrence, but should 
Table 3 – Radiation toxicity by treatment group
Characteristic HDRB LDRB TELE p value*
Acute toxicity (%) 0.239
Absent 66 (84.6) 18 (94.7) 21 (95.4)
Grades 1-2+ 12 (15.4) 1 (5.3) 1 (4.6)
Acute toxicity organs (%) 0.153
Gastrointestinal 0 (0.0) 0 (0.0) 1 (4.6)
Bladder 8 (10.3) 1 (5.3) 0 (0.0)
Vagina 4 (5.1) 0 (0.0) 0 (0.0)
Late toxicity (%) < 0.001
Absent 64 (82.0) 16 (84.2) 15 (68.2)
Grades 1-2+ 14 (18.0) 2 (10.5) 1 (4.6)
Grades 3-5+ 0 (0.0) 1 (5.3) 6 (27.3)
Late toxicity organs (%)
Gastrointestinal 10 (12.8) 1 (5.3) 5 (23.0)
Bladder 1 (1-3) 2 (10.5) 1 (4.6)
Vagina 3 (3.9) 0 (0.0) 1 (4.6) 0.384
*chi-square test; +using the toxicity criteria of the radiation therapy oncology group (RTOG).
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be used only in women aged more than 70 years, in tu-
mors with linfovascular invasion, stage IC14, histological 
grades 2 and 3.
Our series failed to show an association between the 
different adjuvant radiotherapy techniques and improve-
ment in local control or overall survival. An important 
point to note is that patients included in our study had 
better prognostic factors than those described in the pa-
pers cited above. Therefore, the measurement of a ben-
efit, if any, may require a much larger number of women 
to be included, and perhaps a longer follow-up is needed. 
Actually, this study had no statistical power to compare 
these outcomes, due to the very low number of events.
Regarding toxicity, Piver and Hempling7 reported that 
among 92 patients treated with low dose rate brachyther-
apy, 1% had severe toxicity, and of 41 submitted to tele-
therapy, 9% had severe toxicity. Cengiz et al.4 described 
9% of grade 3-4 toxicities with teletherapy in 78 patients 
and no cases of grade 3-4 toxicity in 31 women treated 
with low and high dose rate brachytherapy. Aalders et 
al.13 found that, among 540 patients, two of the brachy-
therapy group had grades 3-4 complications, and three 
of the teletherapy group had grades 3-4 complications. 
The PORTEC study16 described 2% of grades 3-4 toxicity 
in the teletherapy group, with 354 women and the GOG 
9917described 5% of grades 3-4 toxicity in the group of 
190 women subjected to external radiotherapy.
In the present study, grades 3-5 toxicity was 27% in 
the teletherapy group, markedly higher than in the other 
groups, even higher than in the literature. The patients 
who did not receive radiotherapy had the best prognos-
tic factors, and therefore had no postoperative treatment. 
The teletherapy group had worse prognostic factors, what 
induced more aggressive intervention to these patients. 
This historic comparison is very important, because it 
shows progressive changes, during time, in the adjuvant 
radiotherapy magnitude, always based in retrospectives 
studies. In our series, the more aggressive treatment led 
to a worse outcome, due the higher toxicity of telether-
apy, therefore, contraindicated for these patients. There 
was no significant statistical relation between lymphad-
enectomy and higher toxicity, in this series.
Several authors agree on the adjuvant radiotherapy in-
dication for the old FIGO stage IB and grade 3 subgroup, 
giving preference to teletherapy in these cases10,15-19. De-
spite the prevalence of this disease, there is no consensus 
for the adjuvance of cancer of the endometrium stage IA, 
histological grades 1 and 2 patients, due to the lack of 
randomized studies. The findings of the PORTEC16 and 
GOG 9917 studies showed that most recurrences of ini-
tial tumors were limited to vagina, which, added to low 
toxicity of this treatment, encourages the use of adjuvant 
brachytherapy in these cases, but still without strong evi-
dence in the literature.
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